ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a b

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a

Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than avera

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a bi

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026

Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare provid

ROCKVILLE, Md. , May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a b

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performe

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zac

Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2026 sales outlook from $840.000 million-$870.000 m

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.04) per share which missed t

ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a bi

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook

ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report)'s share price crossed above its two

JPMorgan Chase and Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUP

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received a consensus rating of "

A Supernus Pharmaceuticals executive reported the sale of 107,250 Common Stock shares over three day

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Frederick Hudson sold 5,369

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference

Supernus Pharmaceuticals (NASDAQ:SUPN) sees FY2026 sales of $840.000 million-$870.000 million vs $86

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.07) per share which beat the

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

    Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs.

Stocks That Hit 52-Week Lows On Monday